Synopsis

Understanding the cellular interplay in chronic and immunemediated skin diseases is critical to uncover pathogenic nodes earlier in development. This interactive workshop will explorethe immune–stromal–neuronal axis and how it shapes disease progression in conditions such as HS, urticaria, AD, and PN. Through discussion of human-centric approaches, spatial transcriptomics, and next-generation in vitro models, attendees will share insights into how to dissect crosstalk beyond canonical immune mechanisms, building translational strategies that account for heterogeneity, fibrosis, and neuroinflammation.

Key Objectives

• Mapping Cellular Interplay: Explore immune, stromal, and neuronal crosstalk as key drivers of dermatological disease heterogeneity
• Bridging In Vitro and Translational Needs: Identify strategies for incorporating multicellular complexity into human in vitro models, including skin-on-a-chip (SoC) approaches and 3D co-cultures to improve translatability in the absence of reliable small animal models
• Targeting Pathogenic Nodes Early: Discuss approaches to uncover and validate pathogenic checkpoints before patient stratification using molecular profiling and mechanistic insight
• Leveraging Human Data & Spatial Tools: Understand the growing role of single-cell and spatial transcriptomics in deciphering disease-specific inflammation across diverse dermatologic indications

Synopsis

The immunodermatology landscape is rapidly evolving with new targets, modalities, and deeper pathway insights. Success depends not only on selecting the “right” targets and building a future-ready pipeline but also on ensuring that approved therapies reach eligible patients. This integrated session brings together strategic R&D decision-making and real-world implementation challenges to provide a holistic view of innovation and access in dermatology.

Key Objectives

• Prioritize Targets and Pathways: Define criteria for selecting interleukins, immune cells, and mechanisms, leveraging translational insights and early clinical validation
• Design Future-Ready Pipelines: Shape dermatology portfolios strategically—balancing commercial opportunity, patient needs, and long-term differentiation
• Evaluate Innovation & Impact: Apply frameworks to assess clinical and commercial potential, ensuring candidates deliver meaningful innovation and internal buy-in
• Bridge Approval to Access: Address market access, pricing, reimbursement, and adoption barriers; enhance clinician engagement and patient inclusion to close treatment gaps

*Lunch will be served during this workshop at 12pm

Synopsis

With expanding insights into the molecular drivers of dermatologic diseases, discovery and early development teams are increasingly tasked with aligning the right therapeutic modality to complex biological targets. From immune engagement to genetic correction, this workshop explores how new formats like bispecifics, gene therapies, and oligonucleotides are reshaping the future of skin-targeted treatments.

Key Objectives

• Emerging Immune-Engaging Modalities: Bispecifics, trispecifics, and nanobodies for selective immune modulation in dermatologic disease
• Genetic & RNA-Based Approaches: Leveraging gene therapies, siRNA, and antisense technologies to address monogenic and inflammatory skin conditions
• Modality x Route of Administration: Evaluating how topical, oral, subcutaneous, or intradermal routes influence efficacy, tissue penetration, and durability
• Early Modality Selection Strategy: Key considerations for choosing the optimal format based on target biology, disease mechanism, and translation potential